Todd Leff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/920416/publications.pdf

Version: 2024-02-01

186265 276875 3,628 42 28 41 citations h-index g-index papers 63 63 63 4899 citing authors all docs docs citations times ranked

#	Article	IF	Citations
1	PER2 Controls Lipid Metabolism by Direct Regulation of PPARγ. Cell Metabolism, 2010, 12, 509-520.	16.2	400
2	Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia Journal of Clinical Investigation, 1995, 96, 2601-2605.	8.2	248
3	PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy. Diabetes, 2002, 51, 3586-3590.	0.6	246
4	Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone Diabetes, 2000, 49, 539-547.	0.6	218
5	c-Jun N-Terminal Kinase Phosphorylates Peroxisome Proliferator-Activated Receptor-Î ³ 1 and Negatively Regulates Its Transcriptional Activity. Endocrinology, 1999, 140, 392-397.	2.8	216
6	Regulation of Transcription by AMP-activated Protein Kinase. Journal of Biological Chemistry, 2001, 276, 38341-38344.	3.4	181
7	AMP-activated Protein Kinase Regulates HNF4α Transcriptional Activity by Inhibiting Dimer Formation and Decreasing Protein Stability. Journal of Biological Chemistry, 2003, 278, 27495-27501.	3.4	180
8	Adipogenesis and fat-cell function in obesity and diabetes. Trends in Molecular Medicine, 2002, 8, 442-447.	6.7	179
9	Lipolytic Products Activate Peroxisome Proliferator-activated Receptor (PPAR) \hat{l}^{\pm} and \hat{l}^{\prime} in Brown Adipocytes to Match Fatty Acid Oxidation with Supply. Journal of Biological Chemistry, 2012, 287, 25038-25048.	3.4	168
10	Individual products of the adenovirus 12S and 13S Ela mRNAs stimulate viral Ella and EllI expression at the transcriptional level Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 4381-4385.	7.1	158
11	AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochemical Society Transactions, 2003, 31, 224-227.	3.4	150
12	Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice Journal of Clinical Investigation, 1994, 93, 1683-1690.	8.2	125
13	Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma Diabetes, 1999, 48, 254-260.	0.6	108
14	Transcriptional analysis of the adenovirus-5 EIII promoter: absence of sequence specificity for stimulation by Ela gene products. Nucleic Acids Research, 1985, 13, 1209-1221.	14.5	105
15	Selective activation of $PPAR\hat{I}^3$ in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E28-E37.	3.5	93
16	Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor- \hat{l}^3 ligands. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L613-L619.	2.9	69
17	Adiponectin and PPARÎ ³ . Vitamins and Hormones, 2012, 90, 143-162.	1.7	67
18	Lead (Pb) exposure promotes diabetes in obese rodents. Journal of Trace Elements in Medicine and Biology, 2017, 39, 221-226.	3.0	60

#	Article	IF	CITATIONS
19	Alterations in Lipid Signaling Underlie Lipodystrophy Secondary to AGPAT2 Mutations. Diabetes, 2012, 61, 2922-2931.	0.6	56
20	Peroxisomal proliferator activated receptor- \hat{l}^3 deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics, 2006, 7, 3.	2.1	54
21	Diabetes and Exposure to Environmental Lead (Pb). Toxics, 2018, 6, 54.	3.7	54
22	Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-Î ³ . Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1606-1612.	3 . 6	53
23	Far upstream sequences are required for efficient transcription from the adenovirus-2 E1A transcription unit. Nucleic Acids Research, 1983, 11, 8735-8745.	14.5	52
24	Mitogen-activated Protein Kinase Regulates Transcription of the ApoCIII Gene. Journal of Biological Chemistry, 1999, 274, 33050-33056.	3.4	45
25	Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARÎ ³ -dependent autocrine mechanism. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H690-H698.	3.2	41
26	A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes. Endocrinology, 2001, 142, 3207-3213.	2.8	40
27	Thiazolidinedione treatment and constitutiveâ€PPARγ activation induces ectopic adipogenesis and promotes ageâ€related thymic involution. Aging Cell, 2010, 9, 478-489.	6.7	35
28	c-Myc Does Not Require Max for Transcriptional Activity in PC-12 Cells. Molecular and Cellular Neurosciences, 1994, 5, 277-282.	2.2	32
29	Altered Promoter Recycling Rates Contribute to Dominant-Negative Activity of Human Peroxisome Proliferator-Activated Receptor-Î ³ Mutations Associated with Diabetes. Molecular Endocrinology, 2007, 21, 857-864.	3.7	24
30	Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome. Endocrine Practice, 2007, 13, 656-661.	2.1	19
31	Curcumin is not a ligand for peroxisome proliferator-activated receptor-Î ³ . Gene Therapy and Molecular Biology, 2009, 13, 20-25.	1.3	19
32	Three Isoforms of a Hepatocyte Nuclear Factor-4 Transcription Factor with Tissue- and Stage-specific Expression in the Adult Mosquito. Journal of Biological Chemistry, 1998, 273, 29801-29810.	3.4	18
33	Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARÎ ³ deficiency. Journal of Lipid Research, 2012, 53, 1968-1978.	4.2	18
34	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	8.2	17
35	Review: Peroxisome Proliferator-Activated Receptor-Î ³ and Its Role in the Development and Treatment of Diabetes. Experimental Diabesity Research, 2004, 5, 99-109.	1.0	16
36	The Antidiabetic PPARγ Ligands: An Update on Compounds in Development. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2002, 2, 33-47.	0.2	14

TODD LEFF

#	Article	IF	CITATION
37	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	8.2	10
38	Adiponectin secretion from cardiomyocytes produces canonical multimers and partial co-localization with calsequestrin in junctional SR. Molecular and Cellular Biochemistry, 2019, 457, 201-214.	3.1	7
39	Hormonal regulation of glycine decarboxylase and its relationship to oxidative stress. Physiological Reports, 2021, 9, e14991.	1.7	7
40	PPAR \hat{l}^3 mutations, lipodystrophy and diabetes. Hormone Molecular Biology and Clinical Investigation, 2014, 20, 63-70.	0.7	4
41	Studies of heterologous promotertrans-activation by the HTLV-Iltaxprotein. Nucleic Acids Research, 1989, 17, 5737-5749.	14.5	1
42	Characterization of Cardiac Adiponectin Post-Translational Processing and Secretion. Biophysical Journal, 2013, 104, 313a.	0.5	0